E2F transcription factor 2–MyD88 promoter DNA interaction (E2F2–MyD88 promoter interaction)

The E2F transcription factor 2–MyD88 promoter DNA interaction is a specific regulatory event where the E2F2 protein binds to the promoter region of the Myeloid differentiation primary response 88 (MyD88) gene to drive its transcription [1.2.1]. While E2F2 is traditionally recognized for its role in cell cycle progression, particularly the G1/S transition, its interaction with the MyD88 promoter has been identified as a key driver of pathological inflammation [1.1.2, 1.2.1]. In conditions like rheumatoid arthritis, elevated E2F2 levels lead to increased MyD88 expression, which in turn activates the PI3K/AKT/NF-κB signaling pathway and triggers the release of proinflammatory cytokines such as TNF-α and IL-1β [1.2.1]. This interaction also plays a role in neuroinflammation, where it has been linked to the development of depression-like symptoms in animal models [1.2.2]. Experimental interventions, such as Morinda officinalis oligosaccharides, have demonstrated the ability to inhibit this binding, thereby reducing inflammatory output and suggesting a novel therapeutic strategy for autoimmune and neuropsychiatric disorders [1.2.2, 1.2.3]. Given the involvement of both E2F2 and MyD88 in tumorigenesis, this interaction is also of significant interest in the context of the cancer-associated inflammatory microenvironment [1.3.1, 1.3.3]. Therapeutic targeting of this interaction must account for the essential roles of E2F2 in normal cell proliferation and MyD88 in innate immunity [1.1.2, 1.3.2].

Other names

E2F2 binding to MyD88 promoterE2F2-mediated MyD88 transcriptionE2F2-MyD88 axisE2F2-STAT1/MyD88-Akt axis

Inhibition of transcription factor binding to promoter DNA